تجاوز إلى المحتوى الرئيسي
User Image

ناصر بن محمد بن ناصر الداغري

Professor

أستاذ الكيمياء الحيوية/مشرف كرسي المؤشرات الحيوية للأمراض المزمنة

كلية العلوم
2أ51 مبنى كلية العلوم رقم 5
المنشورات
مقال فى مجلة
2020

Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?

, S Rozenberg 1, N Al-Daghri 2, M Aubertin-Leheudre 3, M-L Brandi 4 5, A Cano 6, P Collins 7 8, C Cooper 9 10 11, A R Genazzani 12, T Hillard 13, J A Kanis 14 15, J-M Kaufman 16, I Lambrinoudaki . 2020

 

Abstract

We provide an evidence base and guidance for the use of menopausal hormone therapy (MHT) for the maintenance of skeletal health and prevention of future fractures in recently menopausal women. Despite controversy over associated side effects, which has limited its use in recent decades, the potential role for MHT soon after menopause in the management of postmenopausal osteoporosis is increasingly recognized. We present a narrative review of the benefits versus risks of using MHT in the management of postmenopausal osteoporosis. Current literature suggests robust anti-fracture efficacy of MHT in patients unselected for low BMD, regardless of concomitant use with progestogens, but with limited evidence of persisting skeletal benefits following cessation of therapy. Side effects include cardiovascular events, thromboembolic disease, stroke and breast cancer, but the benefit-risk profile differs according to the use of opposed versus unopposed oestrogens, type of oestrogen/progestogen, dose and route of delivery and, for cardiovascular events, timing of MHT use. Overall, the benefit-risk profile supports MHT treatment in women who have recently (< 10 years) become menopausal, who have menopausal symptoms and who are less than 60 years old, with a low baseline risk for adverse events. MHT should be considered as an option for the maintenance of skeletal health in women, specifically as an additional benefit in the context of treatment of menopausal symptoms, when commenced at the menopause, or shortly thereafter, in the context of a personalized benefit-risk evaluation.

Keywords: Cardiovascular; Epidemiology; Hormone therapy; Menopause; Osteoporosis; Safety.

نوع عمل المنشور
PHD
رقم المجلد
31
رقم الانشاء
12
مجلة/صحيفة
Osteoporos Int
الصفحات
2271-2286
مزيد من المنشورات
publications

Prediabetes is a reversible, intermediate stage of type 2 diabetes mellitus (T2DM). Lifestyle changes that include healthy diet and exercise can substantially reduce progression to T2DM.

2023
publications

Objectives: To assess circulating fetuin A and fetuin B levels in participants with and without Gestational Diabetes Mellitus (GDM) and to find out their correlations with other different…

2023
publications

Objective: Non-alcoholic fatty liver disease (NAFLD) and Type 2 diabetes mellitus (T2DM) often coexist and drive detrimental effects in a synergistic manner. This study was designed to understand…

2023